Memorial Sloan Kettering Cancer Center-Monmouth

Middletown, New Jersey 07748

2 studies enrolling now · 13 studies all time

What they study most

ATM Gene Mutation, Adjuvant, Advanced Solid Tumors, Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, BRIP1 Gene Mutation, CHEK2 Gene Mutation, Carcinoma, Transitional Cell, EGFR, Early Stage Lung Cancer, Exon 20, Genes, BRCA 1, Hematologic Malignancies

Studies at this site

• A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer — Recruiting now
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• Olaparib In Metastatic Breast Cancer — Running, not enrolling
• Cisplatin vs Paclitaxel for Triple Negative Breast Cancer — Completed
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies — Status unconfirmed
• A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors — Stopped early
• Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors — Completed
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors — Stopped early
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) — Stopped early